Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 937.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,853 shares of the company’s stock after purchasing an additional 94,742 shares during the quarter. Geode Capital Management LLC’s holdings in Avalo Therapeutics were worth $779,000 at the end of the most recent quarter.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $5.04 on Friday. The firm’s fifty day simple moving average is $6.41 and its 200-day simple moving average is $8.41. Avalo Therapeutics, Inc. has a 1-year low of $4.15 and a 1-year high of $17.42.

Analysts Set New Price Targets

AVTX has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $23.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Stifel Nicolaus started coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $36.00 target price for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Piper Sandler initiated coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.